Patents Assigned to Ribon Therapeutics Inc.
  • Quinazolinones as PARP14 inhibitors
    Patent number: 11958837
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: April 16, 2024
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger
  • Pyridazinones as PARP7 inhibtors
    Patent number: 11691969
    Abstract: The present invention relates to pyridazinones and related compounds having Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: July 4, 2023
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Nicholas Robert Perl, Melissa Marie Vasbinder, Kevin Wayne Kuntz
  • Pyridazinones as PARP7 inhibitors
    Patent number: 11566020
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: January 31, 2023
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • Heterobicyclic amides as inhibitors of CD38
    Patent number: 11535621
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: December 27, 2022
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • Screening methods for PARP modulators
    Patent number: 11293927
    Abstract: The present disclosure is related to methods of identifying Poly(ADP-ribose) polymerases (PARP) inhibitors, and the methods of using PARP probes.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: April 5, 2022
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Timothy J. N. Wigle, Danielle J. Blackwell, Kevin Wayne Kuntz, Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger
  • Pyridazinones as PARP7 inhibitors
    Patent number: 11014913
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: May 25, 2021
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • Quinazolinones as PARP14 inhibitors
    Patent number: 11008308
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: May 18, 2021
    Assignee: Ribon Therapeutics Inc.
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger
  • Pyridazinones as PARP7 inhibitors
    Patent number: 10870641
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: December 22, 2020
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • Quinazolinones as PARP14 inhibitors
    Patent number: 10562891
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: February 18, 2020
    Assignee: Ribon Therapeutics Inc.
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger
  • Pyridazinones as PARP7 inhibitors
    Patent number: 10550105
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: February 4, 2020
    Assignee: Ribon Therapeutics Inc.
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz